Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
The latest update is out from MaxCyte ( (MXCT) ).
MaxCyte, Inc. announced the retirement of Art Mandell from its Board of Directors effective December 31, 2024. Mandell has been a pivotal figure in the company’s strategic growth since 2006, contributing to significant milestones such as the company’s public listings and advancements in cell therapy technologies. His departure marks the continuation of MaxCyte’s journey with nine remaining directors, as the company continues to assert its leadership within the cell engineering sector.
More about MaxCyte
MaxCyte, Inc. operates in the cell engineering industry, focusing on providing enabling platform technologies to support the discovery, development, and commercialization of next-generation cell therapeutics. Their flagship product, the ExPERT™ platform, is based on Flow Electroporation® technology, which aids in the expanding cell therapy market, offering solutions across discovery, development, and commercialization stages of cell-based medicines. The company offers a range of instruments, processing assemblies, and software protocols, supported by a robust intellectual property portfolio.
YTD Price Performance: -6.38%
Average Trading Volume: 46,974
Technical Sentiment Consensus Rating: Sell
Current Market Cap: £355.5M
Learn more about MXCT stock on TipRanks’ Stock Analysis page.
